P53 and bcl-2 assessment in serous ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 18, Issue 2, 2008, Pages 241-248

  Palmer, J E ^a   Sant Cassia, L J ^a   Irwin, C J ^a   Morris, A G ^b   Rollason, T P ^c  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Apoptotic markers; bcl 2; p53; Serous ovarian carcinoma

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENES, BCL-2; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40549140814     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01000.x     Document Type: Article

References (37)

1. Akeshima R, Kigawa J, Takahashi M et al. Telomerase activity and p53 dependent apoptosis in ovarian cancer cells. Br J Cancer 2001 84 : 1551 5.
2. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters; Ki67 expression and flow cytometry. Gynecol Oncol 1994 53 : 301 6.
3. Kerns BJO, Jordan PA, Moore MBH et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992 40 : 1047 51.
4. Eltabbakh G, Belinson J, Kennedy A, Biscotti C, Casey G. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Gynecol Oncol 1996 60 : 146.
5. Kastan MB, Canman CE, Leonard CJ. P53 cell cycle control and apoptosis: implications for cancer. Cancer and Metastasis Reviews 1995 14 : 3 15.
6. Skirnisdottir I, Sorbe B, Seidal T. p53, bCl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int J Gynecol Cancer 2001 11 : 147 58.
7. Reles A, Wen WH, Schnider A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001 7 : 2984 97.
8. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and over-expression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997 89 : 932 8.
9. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993 24 : 1175 9.
10. Sagarra RAM, Andrade LALA, Martinez EZ, Pintos GA, Syrjanen KJ, Derchain SFM. p53 and bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer 2002 12 : 720 7.
11. Levesque MA, Katsarod D, Yu H et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995 75 : 1327 58.
12. Comilleri-Broet S, Hardy-Bessard AC, Le Tourneau A et al. HER-2 over-expression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Annals of Oncology 2004 15 : 104 12.
13. Eliopoulos A, Kerr DJ, Herod J et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995 11 : 1217 28.
14. Dakocytomation 2005. Specification sheet monoclonal mouse anti-human BCL-2 oncoprotein. Dako [online]. Available at: url : http://www.dako.co.uk/ prod_download packageinsert.pdf?objectid=104935003. Accessed July 16, 2005.
15. Herod JJO, Eliopoulos AG, Warwick G, Young LS, Kerr DJ. The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996 56 : 2178 84.
16. Skirnisdottir I, Seidal T, Gerdin E, Sorbes B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 2002 12 : 265 76.
17. Scully RE. Histological typing of ovarian tumours, 2nd edn. New York : Springer Verlag, 1999 : 11 53.
18. Diebold J, Baretton G, Felchner M et al. Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996 105 : 341 9.
19. Kupryjanczyk J, Szymanska T, Madry R et al. Evaluation of clinical significance of TP53, BCL-2, BAX, and MEKI expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 2003 88 : 848 54.
20. Viale G, Maisonneuve P, Bonoldi E et al. The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian cancer patients. Annals of Oncology 1997 8 : 469 76.
21. Anttila MA, Hongxiu JI, Juhola MT, Saarikoski SV, Syrjanen KJ. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol 1999 18 : 42 51.
22. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003 91 : 504 12.
23. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by IHC as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1995 76 : 1201 8.
24. Geisler JP, Geisler HE, Miller GA et al. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 2000 77 : 278 87.
25. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, and tumour grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer 2004 14 : 259 70.
26. Howells RE, Holland T, Dhar KK, Redman CWE. Glutathione S transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int J Gynecol Cancer 2001 11 : 107 12.
27. Havrilesky L, Darcy K, Hamdan H et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecol Oncol Group Study. J Clin Oncol 2003 21 : 3814 25.
28. Berker B, Dunder I, Ensari A, Cengiz SD. Prognostic value of p53 accumulation in epithelial ovarian carcinomas. Arch Gynecol Obstet 2002 266 : 205 9.
29. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filipetti F, Martinelli E. Bcl-2 down-regulation is a novel mechanism of paclitaxal resistance. Mol Pharmacol 2003 64 : 51 8.
30. Veripath OncoDiagnostics 2006. Ovarian cancer markers Bcl-2. Veripath OncoDiagnostics [online]. Available at url : http://www.oncodx.com/oco/bcl2.htm. Accessed September 20, 2005.
31. Sengupta PS, McGown AT, Bajaj V et al. P53 and related proteins in epithelial ovarian cancer. Eur J Cancer 2000 36 : 2317 28.
32. Lavarino C, Pilotti S, Oggionni M et al. p53 gene status and response to platinum/paclitaxel based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000 18 : 3936 45.
33. Concin N, Hefler L, van Bavel J et al. Biological markers in pT1 and pT2 ovarian cancer with lymph node metastasis. Gynecol Oncol 2003 89 : 9 15.
34. Marks JR, Davidoff AM, Kerns BJ et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991 51 : 2979 84.
35. Eccles DM, Brett L, Lessells A et al. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992 65 : 40 4.
36. Kupryjanczyk J, Thor AD, Beauchamp R et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993 90 : 4961 5.
37. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL. Spectrum of mutation and frequency of allelic gene deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993 85 : 1513 9.